Why the study?
Does platelet reactivity assessment identify risk for mortality, stent thrombosis, and bleeding in PCI-treated patients on thienopyridine-type P2Y12-inhibitors?
Does platelet reactivity assessment identify risk for mortality, stent thrombosis, and bleeding in PCI-treated patients on thienopyridine-type P2Y12-inhibitors?
Platelet reactivity assessment can effectively stratify PCI patients on thienopyridines into high ischemic risk (HPR) or high bleeding risk (LPR) categories.
May support platelet reactivity testing for post-PCI risk stratification; hypothesis-generating before guiding therapy or changing practice.
Platelet reactivity assessment during thienopyridine-type P2Y12-inhibitors identifies PCI-treated patients at higher risk for mortality and ST (HPR) or at an elevated risk for bleeding (LPR).
No takes yet. Share an insight, caveat, or question.
Aradi et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on Dual antiplatelet therapyMore from European Heart Journal